Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Non - Small Cell Lung Cancer NSCLC × Vinorelbine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 155 Carcinoma, Non-Small-Cell Lung 98 Lung Neoplasms 50 Hodgkin Disease 22 Lymphoma 15 Recurrence 14 Neoplasm Metastasis 14 Triple Negative Breast Neoplasms 13 Neoplasms 12 Prostatic Neoplasms 10 Sarcoma 8 Lymphoma, Non-Hodgkin 8 Uterine Cervical Neoplasms 7 Rhabdomyosarcoma 7 Adenocarcinoma of Lung 7 Lymphoma, Large B-Cell, Diffuse 6 Small Cell Lung Carcinoma 5 Ovarian Neoplasms 5 Mesothelioma, Malignant 5 Breast Neoplasms, Male 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 NSCLC 4 Brain Neoplasms 4 Unspecified Adult Solid Tumor, Protocol Specific 3 Multiple Myeloma 3 Mesothelioma 3 Lymphoma, Mantle-Cell 3 Lymphoma, Large-Cell, Immunoblastic 3 Lymphoma, Follicular 3 Lymphoma, B-Cell, Marginal Zone 3

Interventions

tremelimumab 1 durvalumab 1 Vinorelbine 1 Gemcitabine 1 Erlotinib Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02352948 2024-07-26

ARCTIC

AstraZeneca

Phase 3 Completed

597 enrolled 23 charts

Non - Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡